This week, we have a conversation with Revalesio president Greg Archambeau about tackling strokes, and other conditions, with a novel method.
Revalesio
While the pharmaceutical industry often focuses on complex chemical compounds, Revalesio is pioneering a novel drug class rooted in a surprising field: fluid physics.
Revalesio is also focusing on stroke, a condition in need of new therapies.
Revalesio’s breakthrough therapy, RNS60, is unlike traditional treatments. It uses a proprietary process to create an oxygen-supersaturated saline that harnesses physical forces to fundamentally improve cellular health. By boosting mitochondrial biogenesis and ATP production, the therapy addresses the core of cellular decline.
Revalesio is currently at the frontier of human health with a primary focus on ischemic stroke, where they have already demonstrated game-changing results, with their phase 2 clinical trials showing a 50% reduction in brain loss and a significant reduction in disability for stroke patients.
With a yearly global economic burden of stroke estimated at $890bn, RNS60 has the potential to unlock a new standard of care and drastically reduce hospital stays (from 10.8 days to 6.0 days in high-dose groups).
The platform technology is also being explored for traumatic brain injury (TBI), Alzheimer’s disease, and broader healthy aging and health-span applications.
Led by an executive team with deep roots at Eli Lilly, AbbVie, and Amgen, Revalesio is now moving toward phase 3 trials.
To get in touch with guest suggestions, or to sponsor or advertise on the podcast, please email jim@deeptechdigest.com